POM-V Prescription Required Companion Animal

Cepfenidex 2 mg/ml + 1 mg/ml Eye Drops, Solution for Dogs and Cats

Active ingredients: Chloramphenicol, Dexamethasone

Form

Drops

Species

Cats Dogs

Manufacturer

CP Pharma Handelsgesellschaft mbH

VMD MA No.

20916/3018

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Chloramphenicol + Dexamethas...

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Cepfenidex 2 mg/ml + 1 mg/ml Eye Drops, Solution for Dogs and Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Put one drop (one drop contains 0.06 mg chloramphenicol and 0.03 mg
dexamethasone) in the conjunctival sac of the affected eye, if necessary in both
eyes; initially 6-8 times a day, then 4-6 times a day. Severe eye disease may require
more frequent dosing (one drop every 1-2 hours) for the first 24-48 hours.
The veterinary medicinal product should only be used until the inflammatory
symptoms have subsided. Subsequently, treatment should be continued with a
monopreparation containing an antibiotic.

Issued August 2024

Do not use in cases of:
- hypersensitivity to the active substance or to any of the excipients;

Issued August 2024
- viral and fungal infections of the eye;
- corneal ulcers and corneal perforations.

Dog and cat:
Rare (1 to 10 animals /
10,000 animals treated):
Allergic reaction, Corneal opacity
Undetermined frequency
(cannot be estimated from the
available data)
Ocular burn
, Increased intra-ocular pressure
,
Glaucoma
, Cataract
, Exopthalmia
1
superficial, temporarily
when the drops are administered, temporarily.
can occur after several weeks of treatment with dexamethasone. A glucocorticoid-
induced increase in intraocular pressure is usually observed within the first 2 weeks
after initiation of therapy.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.

Before starting treatment, it should be ensured that there are no mechanical or
physical causes for the eye inflammation e.g. ectopic eyelash, entropion (inverted
eyelids), foreign body, deficiency in tear secretion.
Cross-resistance has been shown between chloramphenicol and others phenicols.
Use of the product should be carefully considered when susceptibility testing has
shown resistance to phenicols because its effectiveness may be reduced.

Special precautions for safe use in the target species:
Local application of glucocorticoids delays the healing of corneal injuries. Before
starting treatment, it should be ensured that there are no corneal ulcers or
mechanical causes of the eye inflammation.
Because of the possible systemic effects of corticosteroids and effects on cornea, a
long-term use of the veterinary product is not recommended.
Long-term (several months) use of glucocorticoids makes the cornea susceptible to
ulceration and can cause corneal and lens opacification.
Use of the product should be based on identification and susceptibility testing of the
target pathogen(s). If this is not possible, therapy should be based on
epidemiological information and knowledge of susceptibility of the target pathogens
at farm level, or at local/regional level.
Use of the product should be in accordance with official, national and regional
antimicrobial policies.
An antibiotic with a lower risk of antimicrobial resistance selection (lower AMEG
category) should be used for first line treatment where susceptibility testing suggests
the likely efficacy of this approach.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
Dexamethasone, chloramphenicol and benzalkonium chloride can cause allergic
reactions. People with known hypersensitivity to dexamethasone, chloramphenicol
and/or benzalkonium chloride should only administer the veterinary medicinal product
with disposable gloves.
In humans, there is evidence that exposure to chloramphenicol may increase the risk
of severe aplastic anaemia.
It is therefore essential to avoid skin and eye contact and wash hands after
administration of the veterinary medicinal product. In case of accidental skin or eye
contact, flush with plenty of water. In the event of hypersensitivity reactions, seek
medical advice and show the package leaflet or the label to the physician.
Dexamethasone and chloramphenicol may cause serious harm to the unborn child
and children who are breastfed. The veterinary medicinal product should therefore
not be administered by pregnant and breastfeeding women.

Issued August 2024
Special precautions for the protection of the environment:
Not applicable.

No data available.

Store in a refrigerator (2C – 8C).
Keep the container in the outer carton in order to protect from light.

Not applicable.
4.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.